Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Palisade Bio, Inc. (PALI)
Company Research
Source: GlobeNewswire
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company determined to cancel its previously adjourned special meeting of stockholders (the “Special Meeting”), which had been scheduled to reconvene on Friday, October 10, 2025, at 10:00 a.m. Pacific Time. The Special Meeting was previously adjourned to, and reconvened on, September 26, 2025, but was adjourned again without any business being conducted, due to the lack of the required quorum as of the meeting time. As of today, the Company has still not received proxies that would constitute a quorum and has decided to cancel the Special Meeting and to withdraw from consideration by the Company’s stockholders the proposals set forth in the definitive proxy statement filed with the U.S.
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical DevelopmentGlobeNewswire
- Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Individual investors are Palisade Bio, Inc.'s (NASDAQ:PALI) biggest owners and were rewarded after market cap rose by US$70m last week [Yahoo! Finance]Yahoo! Finance
- Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical OperationsGlobeNewswire
PALI
Analyst Actions
- 11/11/25 - Citigroup Inc.
PALI
Sec Filings
- 12/4/25 - Form 8-K
- 11/12/25 - Form S-8
- 11/10/25 - Form 10-Q
- PALI's page on the SEC website